Growth hormone peptides
Ipamorelin vs GHRP-6 and GHRP-2: what the selectivity data measured, and in which species
EC
· 9 min read
A summary of published research, with citations. It states no amount, schedule or route, and makes no claim about what this compound does in a person. Supplied for laboratory research use only.
On this page · 8 sections
Ipamorelin, GHRP-6 and GHRP-2 all release growth hormone through the same ghrelin receptor. The difference is selectivity: in the 1998 paper that introduced ipamorelin, GHRP-6 and GHRP-2 raised ACTH and cortisol in swine while ipamorelin did not. That finding is real and specific. It was made in pigs, prolactin did not separate the compounds in that study, appetite was not measured, and no published human trial has compared ipamorelin with either GHRP directly.

Three compounds, one receptor
All three are synthetic agonists at the growth hormone secretagogue receptor, the receptor Howard and colleagues cloned in 1996 (PMID 8688086) and whose natural ligand, ghrelin, was identified three years later. None of them acts at the GHRH receptor. The broader map of both receptor families, and which molecules sit in each, is in growth hormone secretagogues explained.
| GHRP-6 | GHRP-2 | Ipamorelin | |
|---|---|---|---|
| Structure | Hexapeptide | Hexapeptide (also called pralmorelin) | Pentapeptide: Aib-His-D-2-Nal-D-Phe-Lys-NH2 |
| Origin | Bowers and colleagues, among the first GHRPs | A more potent analogue of GHRP-6 | Novo Nordisk chemistry programme, published 1998 |
| ACTH and cortisol, in swine | Raised | Raised | Not different from GHRH |
| ACTH, cortisol and prolactin, in humans | — | Raised (Arvat 1997) | No published comparison found |
| Appetite | Central administration stimulated eating in rats | Not covered by the sources here | Not measured in the selectivity work |
| Regulatory status | Approved nowhere | Used in Japan as a diagnostic stimulation test; no Canadian, US or EU approval found | Approved nowhere |
Bowers described the GHRPs as a chemical class that releases growth hormone through a dual action on hypothalamus and pituitary, built before anyone knew which receptor they used (PMID 9893708). Ipamorelin came out of a later programme at Novo Nordisk that started from GHRP-1 and removed its central Ala-Trp dipeptide.
What Raun 1998 actually did
The paper that every ipamorelin summary leans on is Raun and colleagues, "Ipamorelin, the first selective growth hormone secretagogue" (PMID 9849822). It is worth reading in the order its experiments were done, because the selectivity claim comes from only one of them.
In vitro, rat pituitary cells. Ipamorelin released growth hormone with potency and efficacy similar to GHRP-6. The half-maximal concentrations were in the same low-nanomolar range, and ipamorelin's maximal response was 85% of GHRP-6's. Experiments with GHRP and GHRH antagonists indicated that ipamorelin acted through the GHRP receptor, not the GHRH receptor.
Anaesthetised rats. Growth hormone release was again comparable to GHRP-6 in potency and efficacy.
Conscious swine. Ipamorelin and GHRP-6 were again closely matched for growth hormone release. GHRP-2 was more potent but reached a lower maximal response.
Specificity, in swine only. This is the experiment the word "selective" refers to. None of the three compounds changed FSH, LH, prolactin or TSH. GHRP-6 and GHRP-2 both raised ACTH and cortisol. Ipamorelin did not raise ACTH or cortisol beyond the levels seen after GHRH, and the authors report that this held even at amounts more than 200 times the level needed for half-maximal growth hormone release. Their conclusion was that ipamorelin is a ghrelin-receptor agonist with a selectivity for growth hormone release similar to that of GHRH itself.
That is a clean result, and it is the genuine basis for treating ipamorelin differently from the earlier GHRPs. It is also a result about pigs.
The prolactin claim does not come from that paper
Ipamorelin is routinely described as "not raising prolactin, unlike GHRP-6 and GHRP-2". In Raun's swine data, no compound raised prolactin, so prolactin did not distinguish ipamorelin from either GHRP in that study.
The prolactin signal for the GHRPs comes from human work. Arvat and colleagues gave GHRP-2 and hexarelin to six healthy young adults and compared them with GHRH, TRH and corticotropin-releasing hormone (PMID 9285939). Both peptides produced strong growth hormone responses and were "not fully specific": they raised prolactin, ACTH and cortisol. The prolactin response was smaller than that to TRH; the ACTH and cortisol responses were similar to those from corticotropin-releasing hormone.
Put the two papers side by side and the honest comparison is narrower than the usual one. GHRP-2 raises prolactin, ACTH and cortisol in humans. GHRP-2 and GHRP-6 raise ACTH and cortisol in swine. Ipamorelin does not raise ACTH or cortisol in swine. Whether ipamorelin spares prolactin, ACTH and cortisol in humans has not been established by a published head-to-head study that we could find.
Appetite: measured for GHRP-6, not for ipamorelin's selectivity
The ghrelin receptor is expressed in the hypothalamus, and ghrelin is an appetite signal, so feeding effects are expected across this class.
For GHRP-6 there is direct animal evidence. Locke and colleagues gave GHRP-6 into the cerebral ventricles of sated rats and found that the incidence of eating rose in step with the amount given, with no matching change in plasma growth hormone — the feeding effect appeared independent of growth hormone release (PMID 8614257). Lawrence and colleagues later showed that central ghrelin and GHRP-6 both stimulated food intake in rats, that the effect was blocked by a neuropeptide Y receptor antagonist, and that both activated hypothalamic and brainstem appetite regions (PMID 11751604).
Raun's paper did not measure appetite or food intake. Claims that ipamorelin "does not stimulate hunger" therefore do not come from the selectivity work. The nearest relevant human evidence is indirect: ipamorelin was taken into a phase 2 trial for postoperative ileus because ghrelin-receptor agonism affects gut motility. Beck and colleagues randomised 117 bowel-resection patients and found median time to first tolerated meal of 25.3 hours with ipamorelin against 32.6 hours with placebo, a difference that was not statistically significant (PMID 25331030). That trial asked about gut recovery after surgery; it is not an appetite study, and its result was null on its key endpoint.
What human data exist for ipamorelin itself
Very little. Gobburu and colleagues ran an escalating-exposure pharmacokinetic and pharmacodynamic study in healthy male volunteers, eight per level (PMID 10496658). They reported a terminal half-life of about two hours and a single episode of growth hormone release peaking at about forty minutes, declining to negligible levels at every level studied. The study measured ipamorelin and growth hormone. It did not report cortisol, prolactin or appetite, so it neither confirms nor contradicts the swine selectivity finding.
That leaves the comparison in this state:
- Growth hormone release: ipamorelin and GHRP-6 comparable in rat cells, rats and swine.
- ACTH and cortisol: ipamorelin separated from GHRP-6 and GHRP-2 in swine. No human comparison found.
- Prolactin: no separation in swine; GHRP-2 raises it in humans; no human data for ipamorelin found.
- Appetite: GHRP-6 stimulates feeding in rats; ipamorelin's appetite effect not addressed by the selectivity work.
Why the species matters
Endocrine responses to ghrelin-receptor agonists are not conserved one-for-one across species. Raun's own data show this within a single paper: GHRP-2 was more potent than GHRP-6 in swine but reached a lower maximal response, a ranking that need not hold elsewhere. The hypothalamic-pituitary-adrenal axis is regulated differently in pigs and people, and an absence of cortisol response in one is a hypothesis for the other, not a measurement of it.
None of this makes the original finding weak. It makes it a finding about the system it was measured in, which is the reading how to read a peptide study applies to every animal result. Ipamorelin half-life and selectivity covers why both half-life and selectivity figures depend on the assay that produced them, and ipamorelin and somatopause covers the ageing hypothesis it is most often discussed under.
Regulatory position
Ipamorelin and GHRP-6 are approved nowhere. GHRP-2 has a diagnostic use in Japan as a growth hormone stimulation test and no Canadian, US or EU approval that we could find. Health Canada's April 2026 advisory on unauthorized peptides names ipamorelin among its examples. All three are prohibited in sport as growth hormone secretagogues on the World Anti-Doping Agency's list.
NovaEvum supplies ipamorelin as a laboratory reagent. GHRP-6 and GHRP-2 are not sold here. For the GHRH-receptor compound often paired with ipamorelin in research discussions, see the CJC-1295 and ipamorelin guide.
Supplied here for laboratory use: Ipamorelin. The laboratory's certificate for each lot is linked from its product page. For laboratory research use only.
Nothing here is medical, dosing, or therapeutic guidance.
Frequently asked questions
Is ipamorelin more selective than GHRP-6? In the 1998 swine study that introduced it, yes, for ACTH and cortisol: GHRP-6 raised both and ipamorelin did not exceed the levels seen after GHRH. Growth hormone release was similar. No published human head-to-head comparison was found, so the selectivity has been demonstrated in pigs, not people.
Does GHRP-2 raise prolactin? In healthy young adults, Arvat and colleagues reported that GHRP-2 and hexarelin raised prolactin, ACTH and cortisol as well as growth hormone. The prolactin response was smaller than that from TRH. In Raun's swine study, by contrast, none of the compounds tested, GHRP-2 included, changed prolactin.
Why is GHRP-6 associated with hunger? Because rat studies showed that centrally administered GHRP-6 stimulates eating, apparently independently of growth hormone release, and activates hypothalamic appetite regions through a neuropeptide Y-dependent pathway. That fits the ghrelin receptor's role as an appetite signal. Whether ipamorelin differs on appetite was not tested in the selectivity paper.
What is ipamorelin's half-life in humans? Gobburu and colleagues reported a terminal half-life of about two hours in healthy male volunteers, with a single growth hormone peak at about forty minutes. Plasma half-life and the duration of the hormonal response are different quantities, and that study measured both separately.
Is GHRP-2 an approved drug? It has a diagnostic role in Japan, where a GHRP-2 stimulation test is used to assess growth hormone deficiency. No Canadian, US or EU approval was found, and NovaEvum does not sell it.
Selected Research References
- Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552-561. pubmed.ncbi.nlm.nih.gov/9849822
- Arvat E, di Vito L, Maccagno B, et al. Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH. Peptides. 1997;18(6):885-891. pubmed.ncbi.nlm.nih.gov/9285939
- Bowers CY. Growth hormone-releasing peptide (GHRP). Cellular and Molecular Life Sciences. 1998;54(12):1316-1329. pubmed.ncbi.nlm.nih.gov/9893708
- Howard AD, Feighner SD, Cully DF, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273(5277):974-977. pubmed.ncbi.nlm.nih.gov/8688086
- Locke W, Kirgis HD, Bowers CY, Abdoh AA. Intracerebroventricular growth-hormone-releasing peptide-6 stimulates eating without affecting plasma growth hormone responses in rats. Life Sciences. 1995;56(16):1347-1352. pubmed.ncbi.nlm.nih.gov/8614257
- Lawrence CB, Snape AC, Baudoin FM, Luckman SM. Acute central ghrelin and GH secretagogues induce feeding and activate brain appetite centers. Endocrinology. 2002;143(1):155-162. pubmed.ncbi.nlm.nih.gov/11751604
- Gobburu JV, Agersø H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research. 1999;16(9):1412-1416. pubmed.ncbi.nlm.nih.gov/10496658
- Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International Journal of Colorectal Disease. 2014;29(12):1527-1534. pubmed.ncbi.nlm.nih.gov/25331030
All products sold by NovaEvum are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease.
